Article: DRUG CAPSULE WHAT Y0U SHOULD KNOW

Article: LUNESTA(TM) Brand Eszopiclone, Formerly ESTORRA, Approved ...
PR Newswire;  December 16, 2004 ;     700+ words ... ... approved the New Drug Application (NDA) for LUNESTA(TM) brand eszopiclone, formerly referred ... for the FDA's decision to not limit LUNESTA's indication to short-term use. Sepracor ... study with no evidence of tolerance." LUNESTA is indicated for the treatment of patients ...

Article: LUNESTA(TM) Data Presented at American College of ...
Business Wire;  November 15, 2005 ;     700+ words ... ... evaluating the safety and efficacy of LUNESTA(TM) brand eszopiclone for the treatment ... Diego. In this study, nightly use of LUNESTA 3 mg resulted in statistically significant ... Compared to placebo, patients administered LUNESTA also reported improvements in sleep quality ...

Article: LUNESTA(TM) Perimenopause-Menopause Study Data to Be ...
Business Wire;  September 30, 2005 ;     700+ words ... ... study evaluating safety and efficacy of LUNESTA(TM) brand eszopiclone for treatment ... placebo-controlled study, nightly use of LUNESTA 3 mg resulted in statistically significant ... treatment period. Patients treated with LUNESTA also demonstrated significant improvements ...

Article: Lunesta Data to Be Presented at American Psychiatric ...
Business Wire;  May 19, 2005 ;     700+ words ... ... that Phase III/IV clinical data for LUNESTA(TM) brand eszopiclone for the treatment ... Primary Insomnia Sepracor will also have a LUNESTA Booth (booth #2742) at APA from May ... began full-scale commercial launch of LUNESTA. LUNESTA, which is indicated for the ...

Article: Results of Sepracor's LUNESTA(R) Next-Day Driving Study in ...
Business Wire;  December 6, 2006 ;     700+ words ... ... presentation of results from a study of LUNESTA([R]) brand eszopiclone that measured ... with primary insomnia administered either LUNESTA 3 mg or placebo the evening before. Next ... following nighttime administration of LUNESTA 3 mg, compared with placebo. Consistent ...

Article: LUNESTA Perimenopause-Menopause Study Shows Improvement ...
Business Wire;  July 18, 2005 ;     700+ words ... ... evaluating the safety and efficacy of LUNESTA(TM) brand eszopiclone for the treatment ... 2005. In this study, nightly use of LUNESTA 3 mg resulted in statistically significant ... for each week of the four-week study. LUNESTA was well tolerated over the treatment ...

Article: LUNESTA(R) Next-Day Function and Discontinuation Data from ...
Business Wire;  September 3, 2008 ;     700+ words ...* Elderly patients taking LUNESTA 2 mg showed significant improvements ... period * Elderly patients administered LUNESTA 2 mg showed no evidence of rebound ... today announced the presentation of LUNESTA([R]) brand eszopiclone Phase IV ...